Details

Autor(en) / Beteiligte

• FOUQUET, Coralie
• ANTOINE, Martine
• CADRANEL, Jacques
• ZALCMAN, Gérard
• SOUSSI, Thierry
• TISSERAND, Pascaline
• FAVIS, Reyna
• WISLEZ, Marie
• COMMO, Fréderic
• RABBE, Nathalie
• CARETTE, Marie France
• MILLERON, Bernard
• BARANY, Francis

Titel

Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients Using a functional assay and a universal oligonucleotide array: A prospective study

Ist Teil von

• Clinical cancer research, 2004-05, Vol.10 (10), p.3479-3489

Ort / Verlag

Philadelphia, PA: American Association for Cancer Research

Erscheinungsjahr

2004

Link zum Volltext

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• Molecular profiling of alterations associated with lung cancer holds the promise to define clinical parameters such as response to treatment or survival. Because <5% of small cell lung cancers and <30% of non-small cell lung cancers are surgically resectable, molecular analysis will perforce rely on routinely available clinical samples such as biopsies. Identifying tumor mutations in such samples will require a sensitive and robust technology to overcome signal from excess amounts of normal DNA. p53 mutation status was assessed from the DNA and RNA of biopsies collected prospectively from 83 patients with lung cancer. Biopsies were obtained either by conventional bronchoscopy or computed tomography-guided percutaneous biopsy. Matched surgical specimens were available for 22 patients. Three assays were used: direct sequencing; a functional assay in yeast; and a newly developed PCR/ligase detection reaction/Universal DNA array assay. Using the functional assay, p53 mutation was found in 62% of biopsies and 64% of surgical specimens with a concordance of 80%. The sensitivity of the functional assay was determined to be 5%. Direct sequencing confirmed mutations in 92% of surgical specimens but in only 78% of biopsies. The DNA array confirmed 100% of mutations in both biopsies and surgical specimens. Using this newly developed DNA array, we demonstrate the feasibility of directly identifying p53 mutations in clinical samples containing <5% of tumor cells. The versatility and sensitivity of this new array assay should allow additional development of mutation profiling arrays that could be applied to biological samples with a low tumor cell content such as bronchial aspirates, bronchoalveolar lavage fluid, or serum.